See the DrugPatentWatch profile for Strensiq
What patents cover Strensiq (asfotase alfa)?
Strensiq is the brand name for asfotase alfa, an enzyme replacement therapy. Patents tied to Strensiq typically cover one or more of the following: specific manufacturing/process steps, formulations, delivery or dosing regimens, and protection of particular molecular/biologic compositions.
You’ll see different patent “buckets” depending on the market (US vs. EU vs. other countries) because patent filings and claim scope vary by jurisdiction and by time.
Where can I find the specific US patent numbers for Strensiq?
To identify the exact US patents, you need to search US patent records using combinations of:
- The active ingredient name: asfotase alfa
- The brand name: Strensiq
- Company/assignee (commonly the developer/owner of Strensiq in the US)
In practice, people usually use the USPTO Patent Public Search or a third-party database to run searches across:
- Assignee name
- Inventor names
- Keywords like “asfotase alfa” or “Strensiq”
- Applicant/owner filters
Then they confirm each result’s coverage by checking the abstract, claims, and legal status (active/expired/lapsed).
How do you check whether Strensiq patents are still in force in the US?
Once you find the relevant US patent numbers, you can check:
- Expiration date (based on filing date and term adjustments)
- Maintenance-fee status (for utility patents)
- Any terminal disclaimers
- Legal status events like expiry, re-exam, or withdrawal
For biologics, it can also matter whether the product is protected by other layers such as regulatory exclusivity (which is separate from patent term) and whether there are Orange Book–style listings or other exclusivity registries that apply to the product category.
When would Strensiq US patent protection expire?
Patent expiry depends on the specific US patent(s) you’re looking at (not the brand or the drug class). The earliest expiration among relevant patents that block generic/biosimilar entry is what matters for “when” competitors can launch, but only if claim scope actually blocks infringement and any litigation or settlement does not delay entry.
Are there biosimilar/generic competitors affected by Strensiq US patents?
For an injectable biologic like asfotase alfa, the main competitive question is whether any biosimilar applicants can reference and market the product before the relevant patents (and any applicable exclusivity) expire or are no longer enforceable.
The “entry date” for a biosimilar-like competitor is driven by:
- Whether a biosimilar application is allowed to proceed
- Patent landscape and claim-by-claim infringement assessments
- Any litigation or settlement terms
Quick way to get an exact answer (US patent numbers) if you share one detail
If you tell me either:
1) the company name shown on Strensiq’s US filings/ownership (assignee), or
2) one US patent number you’ve already seen, or
3) the USPTO link / search results you’re looking at,
…I can help you pinpoint which US patents are most relevant (and whether they appear active/expired) based on the information you provide.
---
Sources: none provided.